title: Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility study.
abstract: L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers > 4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day-1 for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a clinical response: complete response in 30% and partial response in 65%. Imaging, ultrasound and mammography revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as 'severe' in 36% and 'moderate' in 30% of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.
authors.affiliation: Department of Surgery, University of Aberdeen, UK.
authors.forename: J
authors.initials: J
authors.lastname: Brittenden
authors.forename: S D
authors.initials: SD
authors.lastname: Heys
authors.forename: I
authors.initials: I
authors.lastname: Miller
authors.forename: T K
authors.initials: TK
authors.lastname: Sarkar
authors.forename: A W
authors.initials: AW
authors.lastname: Hutcheon
authors.forename: G
authors.initials: G
authors.lastname: Needham
authors.forename: F
authors.initials: F
authors.lastname: Gilbert
authors.forename: M
authors.initials: M
authors.lastname: McKean
authors.forename: A K
authors.initials: AK
authors.lastname: Ah-See
authors.forename: O
authors.initials: O
authors.lastname: Eremin
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001120:Arginine / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008327:Mammography; D008408:Mastectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D014463:Ultrasonography; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001120:Arginine; D011241:Prednisone